Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: A dose-finding study

Journal of Neuro-Oncology

Volumn 87, Issue 1, 2008, Pages 79-84

  Fabi, Alessandra ^a   Mirri, Alessandra ^a   Felici, Alessandra ^a   Vidiri, Antonello ^a   Pace, Andrea ^a   Occhipinti, Emanuele ^a   Cognetti, Francesco ^a   Arcangeli, Giorgio ^a   Iandolo, Bruno ^a   Carosi, Maria Antonia ^a   Metro, Giulio ^a   Carapella, Carmine Maria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemo radiotherapy; Gemcitabine; Glioblastoma multiforme; PhaseI study

Indexed keywords

DEXAMETHASONE; GADOLINIUM; GEMCITABINE; METOCLOPRAMIDE; PENTETIC ACID; RANITIDINE; SEROTONIN ANTAGONIST; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPHAGIA; FEMALE; FEVER; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PROGNOSIS; RADIATION DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 38649107067     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9489-x     Document Type: Article

References (28)

1. Stewart LA (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
3. Lawrence TS, Blackstock AW, McGinn C (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13:13-21
4. Crinò L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522-3530
5. Eckel F, Schneider G, Schmid RM (2006) Pancreatic cancer: A review of recent advances. Expert Opin Investig Drugs 15:1395-1410
6. von der Maase H (2001) Gemcitabine-containing regimens in bladder cancer: A new standard of care. Semin Oncol 28(suppl):1-3
7. Lund B, Kristjansen PE, Hansen HH (1993) Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55
8. Plunkett W, Huang P, Xu YZ, et al (1995) Gemcitabine: Metabolism, mechanism of actions and self-potentiation. Semin Oncol 22(suppl):3-10
9. Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
10. Grunewald R, Kantarjian H, Keating MJ et al (1990) Pharmacologically directed design of the dose-rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukaemia. Cancer Res 50:6823-6826
11. Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
12. Ceribelli A, Gridelli C, De Marinis F et al (2003) Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: A randomized phase II study of two different schedules in combination with cisplatin. Cancer 98:337-343
13. Shewach DS, Hahn TM, Chang E et al (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223
14. Milas L, Fuji T, Hunter N et al (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107-114
15. Maraveyas A, Sgouros J, Upadhyay S et al (2005) Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: A phase I study. Br J Cancer 92:815-819
16. Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
17. National Cancer Institute. Common toxicity criteria version 3.0. Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf Cited 23 February 2007
18. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
19. Brazil L, Thomas R, Laing R et al (1997) Verbally administered Barthel Index as functional assessment in brain tumour patients. J Neurooncol 34:187-192
20. Crowley J (ed) (2001) Handbook of statistics in clinical oncology. Marcel Dekker, New York
21. Curran WJ (2002) New chemotherapeutic agents: Update of major chemoradiation trials in solid tumors. Oncology 63(suppl):29-38
22. Carpinelli G, Bucci B, D'Agnano I et al (2006) Gemcitabine treatment of experimental C6 glioma: The effects on cell cycle and apoptotic rate. Anticancer Res 26:3017-3024
23. Rieger J, Durka S, Streffer J et al (1999) Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 365:301-308
24. Weller M, Streffer J, Wick W et al (2001) Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. Cancer 91:423-427
25. Gertler SZ, MacDonald D, Goodyear M et al (2000) NCIC-CTG phase II study of gemcitabine in patients with malignant glioma. Ann Oncol 11:315-318
26. Eisbruch A, Shewach DS, Bradford CR et al (2001) Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 19:792-799
27. Trodella L, Granone P, Valente S et al (2002) Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20:804-810
28. Martin C, Lund B, Anderson H, Thatcher N (1996) Gemcitabine: Once weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 7:351-357